Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
six
months ended in Dec. 2025,
BactiQuant AS receivedkr16.30 Mil more from issuing new shares than it paid to buy back shares.
It receivedkr0.09 Mil from issuing more debt.
It paidkr0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
It receivedkr0.00 Mil from paying cash dividends to shareholders.
It spentkr0.58 Mil on other financial activities.
In all, BactiQuant ASearnedkr15.82 Mil on financial activities for the
six
months ended in Dec. 2025.
BactiQuant AS (OCSE:BACTIQ) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
BactiQuant AS's issuance of stock for the
six
months ended in Dec. 2025 was kr16.30 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
BactiQuant AS's repurchase of stock for the
six
months ended in Dec. 2025 was kr0.00 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
BactiQuant AS's net issuance of debt for the
six
months ended in Dec. 2025 was kr0.09 Mil.
BactiQuant AS receivedkr0.09 Mil from issuing more debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
BactiQuant AS's net issuance of preferred for the
six
months ended in Dec. 2025 was kr0.00 Mil.
BactiQuant AS paidkr0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
BactiQuant AS's cash flow for dividends for the
six
months ended in Dec. 2025 was kr0.00 Mil.
BactiQuant AS receivedkr0.00 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
BactiQuant AS's other financing for the
six
months ended in Dec. 2025 was kr-0.58 Mil.
BactiQuant AS spentkr0.58 Mil on other financial activities.
BactiQuant AS Cash Flow from Financing Related Terms
BactiQuant AS Cash Flow from Financing Historical Data
* Premium members only.
The historical data trend for BactiQuant AS's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BactiQuant AS Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
BactiQuant AS's Cash from Financing for the fiscal year that ended in Dec. 2025 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was kr27.53 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Financing of kr27.53 Mil mean?
BactiQuant AS (OCSE:BACTIQ) has a Cash Flow from Financing of kr27.53 Mil as of Dec. 2025. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for BactiQuant AS and its competitors.
Is BactiQuant AS's Cash Flow from Financing too high?
BactiQuant AS's current Cash Flow from Financing is kr27.53 Mil. Overall, BactiQuant AS has a GF Score™ of 56/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BactiQuant AS's Cash Flow from Financing compare to VLTO and ZWS?
BactiQuant AS's Cash Flow from Financing of kr27.53 Mil can be compared against companies in the Industrial Products industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for an Industrial Products company?
A good Cash Flow from Financing depends on the Industrial Products industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for BactiQuant AS and its competitors. BactiQuant AS's current Cash Flow from Financing is kr27.53 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BactiQuant AS stock overvalued right now?
Based on GuruFocus' analysis, BactiQuant AS (OCSE:BACTIQ) is currently considered Fairly Valued. The stock's GF Value™ is kr2.32, compared to a current price of kr2.33 — trading 0.4% above its estimated fair value. The current Cash Flow from Financing is kr27.53 Mil. BactiQuant AS's overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For BactiQuant AS (OCSE:BACTIQ), the current Cash Flow from Financing is kr27.53 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BactiQuant AS (OCSE:BACTIQ) Overvalued in 2026?
Based on GuruFocus' analysis, BactiQuant AS stock appears to be overvalued.
The current stock price of kr2.33 is trading 0.4% above its estimated GF Value™ of kr2.32.
GuruFocus considers BactiQuant AS to be Fairly Valued.
Key valuation signals for OCSE:BACTIQ:
Cash Flow from Financing: kr27.53 Mil
GF Value™: kr2.32 vs. price of kr2.33 (0.4% above fair value)
No single metric tells the full story. See the OCSE:BACTIQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BactiQuant AS focuses on delivering technology that ensures optimum usage and handling of water around the world. The company's activities include the development, production, sale and service of BactiQuant Online and BactiQuant Mobile Lab with associated test kits/substrate for the quantification and detection of bacteria in water. Its segments are Aquaculture, Data Centres, Oil & Gas, Water Utility, Industry, and Pharma. The group's products are BQ Online 2.0 PRO, BQ Online, BQ Mobile Lab, and Analysis Kits.
56GF Score
Get the complete analysis for OCSE:BACTIQ
Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCSE:BACTIQ has been successfully added to your 
